{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04281485: Phase 3 Interventional Active, not recruiting Duchenne Muscular Dystrophy
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:peboctocogene camaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02716246: Phase 2/Phase 3 Interventional Recruiting MPS IIIA
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:cevaretigene ritoparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:inlezifigene civaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03612869: Phase 2/Phase 3 Interventional Unknown status Mucopolysaccharidosis Type IIIA
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:ifezuntirgene inilparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:laruparetigene zovaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03223194: Phase 1 Interventional Terminated Crigler-Najjar Syndrome
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02702115: Phase 1/Phase 2 Interventional Terminated MPS I
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE